Pacira BioSciences | Sustainability Performance
Develops and commercializes non-opioid pain management and regenerative health solutions, focusing on improving patient outcomes in various medical procedures.
2006
United States
501 - 1,000 employees
Pharmaceuticals
$500M - 1B in revenue
$25M - 100M in profitability
Sustainability Ranking & Industry Benchmark
#5732
Overall#1211
in United States#123
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
- Pacira's Exparel non-opioid pain product faced clinical debate about efficacy.
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$726.0MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
16.1%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
1.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.7
▼ 0.8%
0.7
▼ 0.1%
0.7
▼ 0.5%
0.8
2030Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
50%
Independent Directors
9 out of 18 incl. management
Overall score
42
Environment
22
Social
64
Governance
41
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
